

## SUPPLEMENTARY DATA

**Table 1 of the supplementary data - Comparative of HRQoL analysis of the patients with FCM infusion at three months follow-up.**

Test/Questionnaire	Basal (n = 205)	3 months (n = 52)	P
EQ-5D-3L-mobility, n (%)			
I have no problems walking about	78 (37.7)	22 (42.3)	.842
I have some problems walking about	128 (61.8)	30 (57.7)	.842
I am confined to bed	1 (0.5)	0 (0)	-
EQ-5D-3L-self-care, n (%)			
I have no problems with self-care	150 (72.1)	40 (76.9)	.274
I have some problems washing or dressing myself	50 (24.0)	12 (23.1)	.651
I am unable to wash or dress myself	8 (3.8)	0 (0)	.079
EQ-5D-3L-activities, n (%)			
I have no problems with performing my usual activities	99 (47.8)	23 (44.2)	.843
I have some problems with performing my usual activities	94 (45.4)	28 (53.8)	.844
I am unable to perform my usual activities	14 (6.8)	1 (1.9)	.308
EQ-5D-3L-pain, n (%)			
I have no pain or discomfort	85 (40.9)	19 (36.5)	.839
I have moderate pain or discomfort	103 (49.5)	28 (53.8)	.990
I have extreme pain or discomfort	20 (9.6)	5 (9.6)	.727
EQ-5D-3L-anxiety, n (%)			
I am not anxious or depressed	113 (54.6)	34 (65.4)	.420
I am moderately anxious or depressed	86 (41.5)	16 (30.8)	.410
I am extremely anxious or depressed	8 (3.9)	2 (3.8)	.990
Minnesota Questionnaire			
Q1. Causing swelling in your ankles or legs?	1.53 ±1.62	1.33 ± 1.39	.569
Q2. Making you sit or lie down to rest during the day?	1.96 ±1.67	1.88 ± 1.49	.646
Q3. Making your walking about or climbing stairs difficult?	2.93 ±1.69	2.47 ± 1.78	.179
Q4. Making your working around the house or yard difficult?	2.41 ±1.82	2.06 ± 1.87	.467
Q5. Making your going places away from home difficult?	2.60 ± 1.83	2.35 ± 2.02	.258
Q6. Making your sleeping well at night difficult?	1.98 ±1.68	1.42 ± 1.75	.113
Q7. Making you relating to or doing things with friends or family difficult?	1.32 ±1.56	1.21 ± 1.56	.999
Q8. Making you working to earn a living difficult?	1.58 ±1.97	1.23 ± 1.69	.544
Q9. Making your recreational pastimes, sports, or hobbies difficult?	1.96 ±1.95	1.47 ± 1.68	.550
Q10. Making your sexual activities difficult?	1.68 ±1.92	1.69 ± 1.92	.327

Q11. Making you eat less of the foods you like?	2.03 ±1.76	1.79 ±1.89	.634
Q12. Making you short of breath?	2.19 ±1.75	1.74 ±1.73	.885
Q13. Making you tired, fatigued, or low on energy?	2.51 ±1.74	1.69 ±1.94	.165
Q14. Making your stay in a hospital?	1.30 ±1.67	0.92 ±1.53	.177
Q15. Costing you money for medical care?	1.32 ±1.67	0.96 ±1.43	.061
Q16. Giving you side effects from treatments?	1.00 ±1.45	0.96 ±1.48	.339
Q17. Making you feel you are a burden to your family or friends?	1.25 ±1.66	1.29 ±1.66	.659
Q18. Making you feel a loss of self-control in your life?	1.48 ± 1.76	1.45 ±1.74	.924
Q19. Making you worry?	2.01 ±1.80	1.62 ± 1.80	.172
Q20. Making it difficult for you to concentrate or remember things?	1.78 ±1.71	1.45 ±1.61	.334
Q21. Making you feel depressed?	1.66 ±1.70	1.27 ±1.48	.103
MLHFQ Questionnaire			
Physical dimension	18.4 ±10.8	15.9 ±10.5	.326
Emotional dimension	8.1 ±7.3	7.1 ±7.0	.318
Global score	38.4 ± 26.0	34.9 ±25.2	.334

FCM, ferric carboxymaltose; HRQoL, health-related quality of life; MLHFQ,

Minnesota Living with Heart Failure Questionnaire; Q, question number.

There were 31 patients with incomplete basal EQ-5D-3L and Minnesota test and 147 in the 3 months follow-up.

Data are expressed as no. (%) or mean ± standard deviation.

**Table 2 of the supplementary data - Comparative of the characteristics of the patients at three months according to TSAT level.**

Characteristics	TSAT < 20 (n = 184)			TSAT ≥ 20 (n = 34)			P
	Basal	3 months	P	Basal	3 months	P	
Age (years)	73.2 (10.6)			75.4 (11.6)			.265
Sex (female), n (%)	96 (52.2)			18 (52.9)			.934
SBP (mmHg)	124.4 (18.9)			126.4 (17.0)			.561
HR (bpm)	69.5 (11.9)			67.1 (11.8)			.279
Functional class, n (%)							.101
NYHA I	4 (2.2)	10 (10.0)	.045	3 (9.1)	20 (16.3)	.001	
NYHA II	141 (79.2)	76 (76.0)		26 (78.8)	95 (77.2)		
NYHA III	33 (18.5)	14 (14.0)		4 (14.6)	8 (6.5)		
NYHA improvement ≥1		40 (22.5)			5 (15.2)		.641
NYHA no improvement		133 (74.7)			27 (81.8)		
NYHA deterioration ≥ 1		5 (2.8)			1 (3.0)		
LVEF (%)	44.4 (15.0)			43.7 (15.7)			.805
FCM dose (mg)	951.1 (148.9)			911.8 (193.5)			.180
Theoretical dose, n (%)	82 (44.6)			18 (54.5)			.290
Hb (g/dL)	12.3 (1.5)	12.9 (1.7)	.0001	13.1 (1.4)	13.5 (1.1)	.018	.013
Anemia- n (%)	84 (45.7)			10 (30.3)			.101
MCHC (pg)	28.9 (2.8)	30.3 (2.0)	.0001	30.8 (1.8)	31.7 (1.8)	.012	.0001
MCV (fL)	90.1 (7.9)	94.2 (5.4)	.0001	93.2 (12.5)	98.7 (5.3)	.002	.064
Serum Fe (mcg/dL)	47.1 (16.2)	79.9 (31.8)	.0001	89.8 (21.1)	90.8 (23.9)	.845	.0001
Transferrin (mg/dL)	284.5 (60.8)	232.3 (50.1)	.0001	248.9 (41.5)	210.6 (40.0)	.0001	.001
Ferritin (ng/mL)	64.9 (79.3)	280.1 (393.2)	.0001	108.5 (122.3)	278.8 (124.7)	.0001	.008
TSAT (%)	11.9 (4.1)	24.0 (11.1)	.0001	25.8 (6.4)	29.4 (9.6)	.021	.0001
Absolute ID, n (%)	151 (82.1)	27 (19.4)	.0001	23 (67.6)	1 (4.2)	.0001	.001
NT-proBNP (pg/mL)	4754.0 (6577.4)	3282.4 (3611.8)	.001	3585.4 (4796.3)	2452.2 (2793.7)	.122	.285
Creatinine (mg/dL)	1.3 (0.5)	1.3 (0.4)	.334	1.3 (0.6)	1.3 (0.6)	.955	.881
eGFR (mL/min)	58.5 (23.2)	56.8 (20.9)	.549	54.4 (21.9)	59.7 (24.7)	.746	.367

BMI, body mass index; BPM, beats per minute; DBP, diastolic blood pressure; eGFR, estimated glomerular filtrated rate; FCM, ferric carboxymaltose; Fe, Iron; Hb, hemoglobin; HR, heart rate; ID, iron deficiency; LVEF, left ventricular ejection fraction; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic blood pressure; TSAT, transferrin saturation.

18 patients were excluded from the analysis for incomplete data.

The correct dose was defined according to weight and Hb<sup>3</sup>. Functional ID was defined as ferritin < 100<sup>3</sup>.